Aventis powers drug development with solutions from InnaPhase
The recent announcement expands Aventis' use of the Watson solution to additional facilities. In 1997, Aventis Pharma implemented Watson in its Vitry-Alfortille, France facility and reached a decision to implement the system in its Bridgewater, New Jersey (USA) facility. This most recent agreement also allows Aventis Pharma to license Watson for its Japanese research facility.
According to InnaPhase, the Watson LIMS system is designed to support DMPK/Bioanalytical studies in drug development while ensuring regulatory compliance with the FDA's 21 CFR Part 11 guidance on electronic records and signatures. In addition, Watson has been developed in conjunction with pharmaceutical companies to accelerate bioanalysis and sample management in drug development.
"Automating and streamlining our analytical laboratories are key steps in processing the large number of early development compounds being produced in the discovery labs," said Dennis Giesing, Vice President and Global Head of DMPK, Aventis Pharma. "Our experience with the Watson LIMS in France has been overwhelmingly positive, and we are confident that InnaPhase systems will continue to play a key role in our drug development operations worldwide."
"The unique features that the Watson LIMS provides, allows companies to significantly accelerate turnaround in the analytical labs, while maintaining FDA regulatory compliance," said Peter J.D. Ryan, Chairman and Chief Executive Officer, InnaPhase Corporation. "This can result in major time and cost savings and streamline drug innovation, approval and time to market."